CN110177787A - 整合素拮抗剂 - Google Patents

整合素拮抗剂 Download PDF

Info

Publication number
CN110177787A
CN110177787A CN201780080614.7A CN201780080614A CN110177787A CN 110177787 A CN110177787 A CN 110177787A CN 201780080614 A CN201780080614 A CN 201780080614A CN 110177787 A CN110177787 A CN 110177787A
Authority
CN
China
Prior art keywords
unsubstituted
compound
alkyl
substituted
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780080614.7A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·G·鲁明斯基
大卫·W·格里格斯
科特·赛韦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indaro Medical Co Ltd
St Louis University
Original Assignee
Indaro Medical Co Ltd
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indaro Medical Co Ltd, St Louis University filed Critical Indaro Medical Co Ltd
Publication of CN110177787A publication Critical patent/CN110177787A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780080614.7A 2016-12-29 2017-12-28 整合素拮抗剂 Pending CN110177787A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662440253P 2016-12-29 2016-12-29
US62/440,253 2016-12-29
US201762471882P 2017-03-15 2017-03-15
US62/471,882 2017-03-15
PCT/US2017/068801 WO2018132268A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Publications (1)

Publication Number Publication Date
CN110177787A true CN110177787A (zh) 2019-08-27

Family

ID=62840040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080614.7A Pending CN110177787A (zh) 2016-12-29 2017-12-28 整合素拮抗剂

Country Status (14)

Country Link
US (1) US11306084B2 (https=)
EP (1) EP3562826A4 (https=)
JP (1) JP2020504120A (https=)
KR (1) KR20190100232A (https=)
CN (1) CN110177787A (https=)
AU (1) AU2017393297A1 (https=)
BR (1) BR112019012515A2 (https=)
CA (1) CA3045491A1 (https=)
CO (1) CO2019007023A2 (https=)
IL (1) IL267686A (https=)
MX (1) MX2019007797A (https=)
PH (1) PH12019501514A1 (https=)
RU (1) RU2019116820A (https=)
WO (1) WO2018132268A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177787A (zh) 2016-12-29 2019-08-27 圣路易斯大学 整合素拮抗剂
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
FI3844162T3 (fi) 2018-08-29 2025-03-27 Morphic Therapeutic Inc Alfa v beeta6 -integriinin estäjiä
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
JP2026500719A (ja) * 2022-12-27 2026-01-08 プライアント・セラピューティクス・インコーポレイテッド アルファ－ｖ－ベータ－８インテグリン阻害剤及びその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096334A2 (en) * 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2004058761A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
US20140051715A1 (en) * 2012-07-18 2014-02-20 Saint Louis University 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
CN104640857A (zh) * 2012-07-18 2015-05-20 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572690A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
MX2019005234A (es) 2016-11-08 2019-08-12 Squibb Bristol Myers Co Amidas y aminas de azol como inhibidores de integrina alfa v.
SI3538528T1 (sl) 2016-11-08 2021-03-31 Bristol-Myers Squibb Company Pirol amidi kot alfa v integrin inhibitorji
AU2017359025A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors
KR102506327B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체
WO2018089353A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
CN110177787A (zh) 2016-12-29 2019-08-27 圣路易斯大学 整合素拮抗剂
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020009889A1 (en) 2018-07-03 2020-01-09 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096334A2 (en) * 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2004058761A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
US20140051715A1 (en) * 2012-07-18 2014-02-20 Saint Louis University 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
CN104640857A (zh) * 2012-07-18 2015-05-20 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物

Also Published As

Publication number Publication date
IL267686A (en) 2019-08-29
EP3562826A4 (en) 2020-08-26
US20190345155A1 (en) 2019-11-14
JP2020504120A (ja) 2020-02-06
EP3562826A1 (en) 2019-11-06
WO2018132268A1 (en) 2018-07-19
AU2017393297A1 (en) 2019-06-13
KR20190100232A (ko) 2019-08-28
RU2019116820A (ru) 2021-01-29
PH12019501514A1 (en) 2020-09-14
CA3045491A1 (en) 2018-07-19
US11306084B2 (en) 2022-04-19
MX2019007797A (es) 2019-10-21
WO2018132268A8 (en) 2019-06-20
CO2019007023A2 (es) 2019-07-31
BR112019012515A2 (pt) 2019-11-19

Similar Documents

Publication Publication Date Title
CN104640857B (zh) 作为整合素拮抗剂的β氨基酸衍生物
CN110177787A (zh) 整合素拮抗剂
CN103534240B (zh) 选择性fak抑制剂
CN102656168B (zh) 作为溶血磷脂酸受体拮抗剂的多环化合物
CN104684899B (zh) 取代的磺酰胺化合物
CN106459017B (zh) 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸
RU2729518C2 (ru) Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
US11230532B2 (en) Pyrimidines and variants thereof, and uses therefor
TW202128644A (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
KR20190091564A (ko) 신규한 소염제
KR20140040774A (ko) 이미다조피리딘 화합물
WO2020009889A1 (en) ALPHAvBETA1 INTEGRIN ANTAGONISTS
WO2012039371A1 (ja) シクロプロパン化合物
CN104736533B (zh) Vegfr3抑制剂
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
WO2018145653A1 (zh) 联芳基类化合物及其制备方法和用途
WO2025215121A1 (en) Hedgehog acyltransferase inhibitors
HK40095571A (zh) 作为ddr1和ddr2抑制剂的吲哚啉衍生物
HK1209749B (en) Beta amino acid derivatives as integrin antagonists
HK40127636A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物
HK1245249A1 (zh) 二环喹唑啉酮衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190827